To appraise the clinical and cost effectiveness of sotagliflozin within its marketing authorisation for treating type 1 diabetes.
 
Status In progress
Process STA 2018
ID number 1376

Provisional Schedule

Expected publication 08 January 2020

Project Team

Project lead Jeremy Powell

Email enquiries

Evidence Review Group / Assessment Group Warwick Evidence, Warwick Medical School, University of Warwick

Consultees

Companies sponsors Sanofi (sotagliflozin)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups JDRF
Professional groups Association of British Clinical Diabetologists
  Royal College of Pathologists
  Royal College of Physicians
  UK Clinical Pharmacy Association

Commentators

Associated public health groups Public Health England
  Public Health Wales
Comparator companies Eli Lilly (insulin)
  Novo Nordisk (insulin) (not participating)
  Sanofi (insulin)
  Wockhardt UK (insulin) (not participating)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee

Timeline

Key events during the development of the guidance:

Date Update
22 November 2019 - 06 December 2019 Final appraisal document
26 September 2019 Committee meeting: 2
06 August 2019 After the first Appraisal Committee meeting the Committee requested additional analyses from the company.
30 July 2019 Committee meeting: 1
06 December 2018 Invitation to participate
25 September 2018 Please note that following on from information provided by the company the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in late November 2018.
13 February 2018 In progress, Topic referred

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance